CA2717741C - Treatment of hearing and balance impairments with redox-active therapeutics - Google Patents

Treatment of hearing and balance impairments with redox-active therapeutics Download PDF

Info

Publication number
CA2717741C
CA2717741C CA2717741A CA2717741A CA2717741C CA 2717741 C CA2717741 C CA 2717741C CA 2717741 A CA2717741 A CA 2717741A CA 2717741 A CA2717741 A CA 2717741A CA 2717741 C CA2717741 C CA 2717741C
Authority
CA
Canada
Prior art keywords
alkyl
hydroxy
methyl
composition
redox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2717741A
Other languages
English (en)
French (fr)
Other versions
CA2717741A1 (en
Inventor
Guy M. Miller
Original Assignee
PTC Therapeutics Inc
Bioelectron Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc, Bioelectron Technology Corp filed Critical PTC Therapeutics Inc
Publication of CA2717741A1 publication Critical patent/CA2717741A1/en
Application granted granted Critical
Publication of CA2717741C publication Critical patent/CA2717741C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2717741A 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics Expired - Fee Related CA2717741C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6833008P 2008-03-05 2008-03-05
US61/068,330 2008-03-05
US19119808P 2008-09-05 2008-09-05
US61/191,198 2008-09-05
PCT/US2009/035996 WO2009111543A2 (en) 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics

Publications (2)

Publication Number Publication Date
CA2717741A1 CA2717741A1 (en) 2009-09-11
CA2717741C true CA2717741C (en) 2018-04-03

Family

ID=41056624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717741A Expired - Fee Related CA2717741C (en) 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics

Country Status (5)

Country Link
US (3) US20110046156A1 (enExample)
EP (1) EP2262519A4 (enExample)
JP (4) JP2011513420A (enExample)
CA (1) CA2717741C (enExample)
WO (1) WO2009111543A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
CA2610152C (en) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
EP3018122B1 (en) 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2708961C (en) 2008-01-08 2017-03-28 Ptc Therapeutics, Inc. (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CN102264730B (zh) 2008-10-28 2016-04-13 爱迪生药物公司 用于生产生育三烯酚及衍生物的方法
JP2012525399A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療
SI2470168T1 (en) * 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
EP2519232A1 (en) * 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP2013523816A (ja) * 2010-04-06 2013-06-17 エジソン ファーマシューティカルズ， インコーポレイテッド 毛細血管拡張性運動失調症の治療
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
CA2906145A1 (en) 2013-03-15 2014-09-18 Ptc Therapeutics, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
EP2982382A1 (en) 2014-08-04 2016-02-10 Sensorion Compounds for preventing ototoxicity
WO2016100579A1 (en) * 2014-12-16 2016-06-23 Edison Pharmaceuticals, Inc., Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3767578B1 (en) 2015-04-16 2023-08-16 Honeywell International Inc. Multi-sensor input analysis for improved safety
ES3033538T3 (en) * 2015-10-08 2025-08-05 Khondrion Ip B V Novel compounds for treating mitochondrial disease
WO2017106786A1 (en) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
KR101785455B1 (ko) * 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
JP7586815B2 (ja) 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン
KR102177610B1 (ko) * 2019-03-28 2020-11-11 단국대학교 천안캠퍼스 산학협력단 청각세포와의 공배양을 이용한 배아줄기세포의 내이 세포로의 분화 방법
JP7531808B2 (ja) * 2020-11-04 2024-08-13 国立大学法人 東京大学 騒音性難聴の予防剤
CN118175991A (zh) 2021-07-08 2024-06-11 Ptc医疗公司 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1040908A (en) 1910-09-06 1912-10-08 George E Dunton Composition of matter for use in removing grease, &c., from the molds used in the art of electrotyping.
US1038708A (en) 1911-11-01 1912-09-17 Hipolit Zielinski Wrench.
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US4637402A (en) 1980-04-28 1987-01-20 Adelman Roger A Method for quantitatively measuring a hearing defect
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
WO1993019670A1 (en) 1992-04-04 1993-10-14 Medical Research Council Testing hearing
DE69333575T2 (de) * 1992-05-28 2005-08-25 Centre For Molecular Biology And Medicine, Richmond Quinone-derivate zur verbesserung der zellulare bioenergie
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
DE4402380A1 (de) 1994-01-27 1995-08-03 Hans Peter Prof Dr Med Zenner Implantierbares Dosiersystem
WO1998035658A2 (de) * 1997-02-12 1998-08-20 Mse Pharmazeutika Gmbh Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
ES2209118T3 (es) 1997-02-12 2004-06-16 Mse Pharmazeutika Gmbh Empleo de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona en el tratamiento del zumbido de oidos.
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
WO2002050007A2 (en) * 2000-12-21 2002-06-27 Cancer Research Technology Limited Substituted stilbenes, their reactions and anticancer activity
US7700134B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Prevention of cisplatin induced deafness
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
WO2004093870A1 (en) * 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
KR20070032795A (ko) 2004-06-21 2007-03-22 허치슨 메디파르마 엔터프라이즈 리미티드 항암 화학요법
CA2610152C (en) * 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070021497A1 (en) * 2005-07-11 2007-01-25 The Fruitful Yield Vitamin e compositions
ES2823728T3 (es) 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
EA019675B1 (ru) * 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
US7786100B2 (en) * 2006-03-20 2010-08-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
EP3018122B1 (en) * 2007-11-06 2018-10-10 BioElectron Technology Corporation 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
CA2708961C (en) * 2008-01-08 2017-03-28 Ptc Therapeutics, Inc. (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES

Also Published As

Publication number Publication date
CA2717741A1 (en) 2009-09-11
WO2009111543A3 (en) 2009-12-30
JP2014077019A (ja) 2014-05-01
EP2262519A4 (en) 2011-03-23
US20140249160A1 (en) 2014-09-04
JP2015205938A (ja) 2015-11-19
WO2009111543A2 (en) 2009-09-11
JP2017193590A (ja) 2017-10-26
US20180200248A1 (en) 2018-07-19
JP2011513420A (ja) 2011-04-28
EP2262519A2 (en) 2010-12-22
JP6131200B2 (ja) 2017-05-17
US20110046156A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
US20110046156A1 (en) Treatment of hearing and balance impairments with redox-active therapeutics
Kabir et al. NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer's therapy
US12318391B2 (en) Methods and compositions for the prevention and treatment of hearing loss
JP3568039B2 (ja) アダマンタン誘導体の内耳炎治療向け使用
Taleb et al. Hsp70 inhibits aminoglycoside-induced hearing loss and cochlear hair cell death
JP2022536017A (ja) 精神障害、行動障害、認知障害を処置する方法
Frankiewicz et al. Differential effects of NMDA–receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices
WO2001008705A1 (en) Remedies for neurogenic pains
KR102429935B1 (ko) 귀 장애의 치료에 사용하기 위한 (+)-아자세트론
CN104244950B (zh) 含有西洛他唑及银杏叶提取物作为有效成分的听觉障碍预防或治疗用药物组合物
Gambôa et al. Amikacin ototoxicity: case report and literature review
WO2020235582A1 (ja) 運動ニューロン疾患の予防剤及び／又は治療剤
RU2224519C2 (ru) Антиоксидантное и стимулирующее рост нервных клеток средство
EP1471901B1 (en) Spermidine derivative for the treatment of chronic neurodegenerative diseases
JP2019513780A (ja) 耳疾患の処置における使用のための（＋）−アザセトロン
JP2013014549A (ja) 抗癌剤の副作用軽減剤
KR20130020230A (ko) 네크록스를 유효성분으로 함유하는 난청의 예방 또는 치료용 약학 조성물
WO2004043447A2 (en) Compositions and methods for treating or preventing hearing impairment
US11426415B2 (en) Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
HK40043809A (en) Methods and compositions for the prevention and treatment of hearing loss
HK1249515B (zh) 预防和治疗听力损失的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140228

MKLA Lapsed

Effective date: 20210907

MKLA Lapsed

Effective date: 20200304